Ressources

Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.

Implementing treatment of opioid use disorder in rural settings: A focus on HIV and Hepatitis C prevention and treatment

To describe the epidemiology opioid use disorder in the rural United States as it pertains to HIV and hepatitis C transmission and treatment resources.

Lit review | 2018

Overdose, Equity, Barriers and enablers, Rural/remote, Substitution/OAT

It is time for us all to embrace person-centred language for people in prison and people who were formerly in prison

Commentary | 2022

Legal system/law enforcement, Stigma

Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial

To investigate whether reduction in opioid use differs when treated by either buprenorphine–naloxone (BUP) or methadone (MET) among adults with comorbid opioid use disorder (OUD) and mental disorders.

Original research | 2021

About prescribers, Outcomes, Illegal drugs, Substitution/OAT, Mental health

Methadone diversion as a protective strategy: The harm reduction potential of ‘generous constraints’

Explore how people using methadone self-regulate and reasons for diversion

Original research | 2013

Harm reduction, Policy/Regulatory, About PWUD, Illegal drugs, Substitution/OAT, Social benefits, Diversion

Opioid use disorder treatment disruptions during the early COVID-19 pandemic and other emergent disasters: a scoping review addressing dual public health emergencies

How do public health emergencies impact PWOUD? How can health systems respond to novel public health emergencies to serve PWOUD?

Scoping review | 2021

Policy/Regulatory

Outcomes of Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing

The Ottawa Inner City Health's Managed Opioid Program is the first, to our knowledge, to pair injectable opioid agonist hydromorphone treatment with assisted housing for people experiencing homelessne

Original research | 2021

Evidence base, Wrap-around services, Social services, Outcomes, Housing, Social benefits

Provision of Lower Barrier, Patient-Centred Care and Safer Supply of Substances in the Time of Dual Crises

Commentary | 2021

Policy/Regulatory, Safer supply, Advocacy, About pharmacists, About prescribers, Social services, Injecting drugs, Carries/take-home doses

Tackling the overdose crisis: The role of safe supply

Commentary | 2020

Overdose, Mortality, Policy/Regulatory, Safer supply, Advocacy, Barriers and enablers, Illegal drugs, Injecting drugs

Telehealth-Delivered Opioid Agonist Therapy for the Treatment of Adults with Opioid Use Disorder: Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

This Rapid Response report aims to review the effectiveness of the use of telehealth-delivered OAT compared to standard OAT.

Lit review | 2018

Clinical guidance, Evidence base, Policy/Regulatory, Safer supply, About prescribers

The Global Drug Policy Index 2021 - Analytical report

The Global Drug Policy Index is a unique tool that documents, measures and compares national-level drug policies, providing each country with a score and ranking that shows how much their drug policie

Report | 2021

Policy/Regulatory, Equity

The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data

The impact of COVID-19 on drug overdose-related deaths was examined through a systematic review of the literature and percentage change analyses of surveillance data.

Original research | 2021

Overdose, Mortality, Policy/Regulatory, Safer supply, Decriminalization/legalization, Advocacy, Illegal drugs

Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US

With recent increases in buprenorphine treatment for opioid use disorder (OUD), is buprenorphine misuse increasing in the US?

Original research | 2021

Hesitancy of prescribers , About prescribers, About PWUD, Substitution/OAT

Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program

This study describes the transition of The Spot’s buprenorphine service to telemedicine during the COVID-19 pandemic and one year treatment retention.

Original research | 2021

About prescribers, Outcomes, Substitution/OAT, Digital health

Changing Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic

Infographic | 2021

Overdose, Mortality, Evidence base, Advocacy, Housing, Illegal drugs, Workplace, Rural/remote, Stimulants, Sex/Gender

Changing Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic

Update data from the 2020 preliminary report on opioid-related deaths before and during the pandemic

Report | 2021

Overdose, Mortality, Evidence base, Advocacy, Housing, Illegal drugs, Workplace, Rural/remote, Stimulants, Sex/Gender

Effectiveness of peer recovery support services on stages of the opioid use disorder treatment cascade: a systematic review

Peer recovery support services (PRSS) have been increasingly incorporated during the recovery process for opioid use disorder (OUD), yet little is known about the effects of PRSS on clinical outcomes

Lit review | 2021

Wrap-around services, About PWUD, Social services, Peer/PWLLE program involvement

Harm Reduction in the United States at a Moment of Change; Moving Innovation from Grassroots to Mainstream?

Commentary | 2009

Policy/Regulatory

Heroin Assisted Treatment: The state of play

This briefing paper explores the question of Heroin Assisted Treatment (HAT), examines the growing body of evidence emerging from its clinical use in addiction therapies, and makes recommendations for

Report | 2010

Evidence base, Policy/Regulatory, Advocacy